Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature

Inclusion Criteria

• AIM 1: * Treated for cancer at UPHS with immune checkpoint inhibitor therapy * At least 18 years of age at cancer diagnosis AIM 2: * ≥ 18 years of age * Diagnosis of melanoma and planned to undergo adjuvant therapy with immune checkpoint inhibitors * Able to provide written informed consent

Exclusion Criteria

• AIM 1: * Patient treated with novel investigational agent(s) may be excluded on an agent by agent basis to limit heterogeneity and confounding AIM 2: * Pregnant or breast-feeding: Due to risks and potential harm to the unborn fetus, a negative pregnancy test within 10 days prior to the baseline visit is required in women with child-bearing potential. Due to potential nursing infant harm, women who are currently breast-feeding are not eligible for this study. Women are considered postmenopausal and not of child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea or have had a surgical bilateral oophorectomy or tubal ligation * Prior treatment with ICI therapy * Vulnerable patients, including pregnant women and prisoners * Absolute contraindication to rest/vasodilator stress PET/CT, including: ** Known Mobitz type II AV block, third degree AV block, or sick sinus syndrome, without a pacemaker ** Systolic blood pressure < 90mmHg (average over the month prior to enrollment) ** Known hypersensitivity to regadenson and adenosine (hypersensitivity to one of the two agents is not necessarily exclusionary, but will be reviewed with nuclear cardiology locally or at the core lab) ** Profound sinus bradycardia (heart rate < 40bpm) (average over the month prior to enrollment)